Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $170.00 short call and a strike $175.00 long call offers a potential 21.95% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $170.00 by expiration. The full premium credit of $0.90 would be kept by the premium seller. The risk of $4.10 would be incurred if the stock rose above the $175.00 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 22.9 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
See what the IHS Markit Score report has to say about Allergan plc.
Tue, 06 Nov 2018 13:07:03 +0000
Allergan plc NYSE:AGN
Teva Pharmaceutical’s Performance in the Third Quarter
Mon, 05 Nov 2018 19:50:02 +0000
In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~19% YoY (year-over-year) to $4.5 billion. In the first nine months of this year, Teva’s net revenue fell ~16% YoY to $14.3 billion from $17.0 billion.
How Wall Street Analysts View Teva Pharmaceutical
Mon, 05 Nov 2018 18:17:23 +0000
In October, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend approving Teva Pharmaceutical’s (TEVA) and Celltrion’s Biologics License Application for CT-P10, a proposed biosimilar to Roche’s (RHHBY) Rituxan. The recommended approval of CT-P10 was for three indications: as a monotherapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma as a first-line treatment for B-cell NHL in combination with chemotherapy as a second-line monotherapy for non-progressing B-cell NHL after cyclophosphamide-, vincristine-, or prednisone-based chemotherapy
Allergan to Present at Credit Suisse 27th Annual Healthcare Conference
Mon, 05 Nov 2018 13:00:00 +0000
DUBLIN , Nov. 5, 2018 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Credit Suisse 27 …
4 Days Left Before Allergan plc (NYSE:AGN) Will Be Trading Ex-Dividend,
Sun, 04 Nov 2018 13:34:42 +0000
Attention dividend hunters! Allergan plc (NYSE:AGN) will be distributing its dividend of US$0.72 per share on the 14 December 2018, and will start trading ex-dividend in 4 days time on
Also on Market Tamer…
Follow Us on Facebook